论文部分内容阅读
目的:通过检测CA125、癌抗原15-3、甲胎蛋白来确定各种癌症的诊断。方法:分别测定正常健康妇女50例,卵巢良性肿瘤患者20例和恶性肿瘤患者14例。卵巢癌、乳腺癌、肝癌、结肠癌的患者血清同时做癌抗原125癌胚抗原甲胎蛋白CA15-3项目。结果:肿瘤患者CA125、CEA、CA15-3、AFP的阳性率分别为17.8%、27.69%、14.28%、14.55%。联合测定阳性率为70%。结论:糖类抗原125、癌胚抗原CEA、癌抗原CA15-3、甲胎蛋白AFP同时联合检测可提高卵巢癌、肺癌、膀胱癌、乳腺癌、肝癌、肠癌、骨癌的阳性诊断率能达到早期诊断并及时治疗的目的。
OBJECTIVE: To determine the diagnosis of various cancers by detecting CA125, cancer antigen 15-3, and alpha-fetoprotein. Methods: 50 normal healthy women, 20 benign ovarian tumors and 14 malignant tumors were determined. Ovarian cancer, breast cancer, liver cancer, colon cancer patients while making cancer antigen 125 carcinoembryonic antigen alpha fetoprotein CA15-3 project. Results: The positive rates of CA125, CEA, CA15-3 and AFP in cancer patients were 17.8%, 27.69%, 14.28% and 14.55%, respectively. The combined test positive rate was 70%. Conclusion: The combined detection of carbohydrate antigen 125, carcinoembryonic antigen CEA, CA15-3 and α-fetoprotein AFP can improve the positive diagnostic rate of ovarian cancer, lung cancer, bladder cancer, breast cancer, liver cancer, intestinal cancer and bone cancer To achieve the purpose of early diagnosis and timely treatment.